Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariants Immunity Omicron SARSCoV2 Coronavirus Disease COVID Bivalent mRNA biorxivpreprint EmoryUniversity Stanford NIAIDNews NIH
By Neha MathurNov 2 2022Reviewed by Emily Henderson, B.Sc. In a recent study posted to the bioRxiv* server, researchers at Emory University, Stanford University, and the National Institute of Allergy and Infectious Diseases evaluated whether bivalent coronavirus disease 2019 boosters conferred protection against new Omicron subvariants.
However, after their authorization and uptake, more Omicron subvariants have been identified with mutations in the receptor binding domain that confer them with the potential to escape vaccine sera. In fact, the R346T mutation, which has arisen in many Omicron subvariants, confers them with the potential to escape vaccine-elicited and approved monoclonal antibodies.
Study findings and conclusion Individuals in the study cohorts that received one or two monovalent boosters exhibited much-reduced FRNT titers against Omicron subvariants. The effect was most profound against BA.2.75.2 and BQ.1.1, which have the R346T mutation. On the contrary, BA.5-containing bivalent booster recipients exhibited good neutralizing activity against all Omicron subvariants.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariantsResearchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.
Weiterlesen »
Exploring viral loads of SARS-CoV-2 Omicron BA.5 and BA.2 sublineagesIn a new study, researchers compared the viral loads of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 and BA.2 sublineages.
Weiterlesen »
How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution? evolution SARSCoV2 immunity COVID19 coronavirus covid Omicron
Weiterlesen »
Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severityResearchers estimated the effectiveness of monovalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) infection severity outcomes among adults.
Weiterlesen »
Study evaluates BA.5-bivalent booster against new Omicron sublineagesIn a new study, researchers evaluated the efficacy of four doses of parental messenger ribonucleic acid (mRNA) vaccine and a BA.5-bivalent booster against recently emerged Omicron sublineages. Additionally, they determined whether prior infection improved the effect of a booster vaccination.
Weiterlesen »